

Ellen M Carl

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2840755/publications.pdf>

Version: 2024-02-01

52
papers

1,679
citations

279487

23
h-index

288905

40
g-index

52
all docs

52
docs citations

52
times ranked

2139
citing authors

#	ARTICLE	IF	CITATIONS
1	Methodological Investigation of Time Perspective Scoring and Quality of Life among Individuals with Multiple Sclerosis. <i>International Journal of Environmental Research and Public Health</i> , 2022, 19, 5038.	1.2	0
2	The Emerging Global Tobacco Treatment Workforce: Characteristics of Tobacco Treatment Specialists Trained in Council-Accredited Training Programs from 2017 to 2019. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 2416.	1.2	13
3	Future Thinking Priming Especially Effective at Modifying Delay Discounting Rates among Cigarette Smokers. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 8717.	1.2	3
4	Increasing Physical Activity among Breast Cancer Survivors by Modulating Temporal Orientation with rTMS: Feasibility and Potential Efficacy. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 10052.	1.2	1
5	Internal Validity of Two Promising Methods of Altering Temporal Orientation among Cigarette Smokers. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 12601.	1.2	2
6	Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study. <i>Multiple Sclerosis Journal</i> , 2020, 26, 322-332.	1.4	28
7	Slowing of brain atrophy with teriflunomide and delayed conversion to clinically definite MS. <i>Therapeutic Advances in Neurological Disorders</i> , 2020, 13, 175628642097075.	1.5	7
8	Tobacco Dependence Treatment in Oncology: Initial Patient Clinical Characteristics and Outcomes from Roswell Park Comprehensive Cancer Center. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 3907.	1.2	12
9	Aging and Brain Atrophy in Multiple Sclerosis. <i>Journal of Neuroimaging</i> , 2019, 29, 527-535.	1.0	33
10	Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 344.	1.0	17
11	Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 27, 65-73.	0.9	6
12	Complementary and Alternative Medicine Usage by Multiple Sclerosis Patients: Results from a Prospective Clinical Study. <i>Journal of Alternative and Complementary Medicine</i> , 2018, 24, 596-602.	2.1	31
13	Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study. <i>Journal of the Neurological Sciences</i> , 2018, 387, 152-156.	0.3	7
14	Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures. <i>Journal of the Neurological Sciences</i> , 2018, 388, 175-181.	0.3	15
15	Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine. <i>American Journal of Neuroradiology</i> , 2018, 39, 2237-2242.	1.2	25
16	The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing/Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study. <i>CNS Drugs</i> , 2018, 32, 763-770.	2.7	14
17	Jugular Venous Flow Quantification Using Doppler Sonography. <i>Ultrasound in Medicine and Biology</i> , 2018, 44, 1762-1769.	0.7	12
18	Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis. <i>Radiology</i> , 2018, 289, 487-496.	3.6	75

#	ARTICLE	IF	CITATIONS
19	An Observational Study to Assess Brain MRI Change and Disease Progression in Multiple Sclerosis Clinical Practice—The MS&M&RIUS Study. <i>Journal of Neuroimaging</i> , 2017, 27, 339-347.	1.0	14
20	Cardiovascular risk factors are associated with increased lesion burden and brain atrophy in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-310051.	0.9	95
21	Cognitive reserve moderates the impact of subcortical gray matter atrophy on neuropsychological status in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 36-42.	1.4	53
22	Humoral response to EBV is associated with cortical atrophy and lesion burden in patients with MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e190.	3.1	39
23	Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 937-943.	0.9	15
24	A pilot, longitudinal, 24-week study to evaluate the effect of interferon beta-1a subcutaneous on changes in susceptibility-weighted imaging-filtered phase assessment of lesions and subcortical deep-gray matter in relapsing&remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2015, 8, 59-70.	1.5	5
25	Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing&remitting multiple sclerosis over 24 weeks of therapy with subcutaneous interferon beta-1a three times weekly. <i>Journal of Neuroimmunology</i> , 2015, 281, 44-50.	1.1	3
26	Prospective randomized trial of venous angioplasty in MS (PREMiSe). <i>Neurology</i> , 2014, 83, 441-449.	1.5	43
27	Humoral responses to herpesviruses are associated with neurodegeneration after a demyelinating event: Results from the Multi-Center SET study. <i>Journal of Neuroimmunology</i> , 2014, 273, 58-64.	1.1	21
28	Aqueductal cerebrospinal fluid pulsatility in healthy individuals is affected by impaired cerebral venous outflow. <i>Journal of Magnetic Resonance Imaging</i> , 2014, 40, 1215-1222.	1.9	31
29	Diffusion tensor MRI alterations of subcortical deep gray matter in clinically isolated syndrome. <i>Journal of the Neurological Sciences</i> , 2014, 338, 128-134.	0.3	20
30	Chronic cerebrospinal venous insufficiency is not associated with cognitive impairment in multiple sclerosis. <i>BMC Medicine</i> , 2013, 11, 167.	2.3	5
31	Retinal nerve fiber thickness and MRI white matter abnormalities in healthy relatives of multiple sclerosis patients. <i>Clinical Neurology and Neurosurgery</i> , 2013, 115, S49-S54.	0.6	2
32	Multimodal noninvasive and invasive imaging of extracranial venous abnormalities indicative of CCSVI: Results of the PREMiSe pilot study. <i>BMC Neurology</i> , 2013, 13, 151.	0.8	15
33	Changes of Cine Cerebrospinal Fluid Dynamics in Patients with Multiple Sclerosis Treated with Percutaneous Transluminal Angioplasty: A Case-control Study. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 829-838.	0.2	31
34	Comparison of Intravascular Ultrasound with Conventional Venography for Detection of Extracranial Venous Abnormalities Indicative of Chronic Cerebrospinal Venous Insufficiency. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 1487-1498.e1.	0.2	25
35	Thalamic Atrophy Is Associated with Development of Clinically Definite Multiple Sclerosis. <i>Radiology</i> , 2013, 268, 831-841.	3.6	145
36	Interdependence and contributions of sun exposure and vitamin D to MRI measures in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1075-1081.	0.9	36

#	ARTICLE	IF	CITATIONS
37	Iron content of the pulvinar nucleus of the thalamus is increased in adolescent multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 567-576.	1.4	28
38	Gray matter SWI-filtered phase and atrophy are linked to disability in MS. <i>Frontiers in Bioscience - Elite</i> , 2013, E5, 525-532.	0.9	24
39	Comparison of Standard 1.5 T vs. 3 T Optimized Protocols in Patients Treated with Glatiramer Acetate. A Serial MRI Pilot Study. <i>International Journal of Molecular Sciences</i> , 2012, 13, 5659-5673.	1.8	1
40	Heart disease, overweight, and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities. <i>Neurological Research</i> , 2012, 34, 819-827.	0.6	16
41	Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis. <i>Neurological Research</i> , 2012, 34, 793-801.	0.6	8
42	Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. <i>BMC Neurology</i> , 2012, 12, 26.	0.8	15
43	Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis. <i>NeuroImage</i> , 2012, 59, 331-339.	2.1	176
44	Iron deposition in multiple sclerosis lesions measured by susceptibility-weighted imaging filtered phase: A case control study. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 36, 73-83.	1.9	60
45	Patterns of dietary and herbal supplement use by multiple sclerosis patients. <i>Journal of Neurology</i> , 2012, 259, 637-644.	1.8	29
46	Associations of moderate alcohol consumption with clinical and MRI measures in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2012, 243, 61-68.	1.1	27
47	Risk Factors for Chronic Cerebrospinal Venous Insufficiency (CCSVI) in a Large Cohort of Volunteers. <i>PLoS ONE</i> , 2011, 6, e28062.	1.1	40
48	Decreased brain venous vasculature visibility on susceptibility-weighted imaging venography in patients with multiple sclerosis is related to chronic cerebrospinal venous insufficiency. <i>BMC Neurology</i> , 2011, 11, 128.	0.8	50
49	Hypoperfusion of brain parenchyma is associated with the severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis: a cross-sectional preliminary report. <i>BMC Medicine</i> , 2011, 9, 22.	2.3	77
50	Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2011, 8, 127.	3.1	186
51	Chronic Cerebrospinal Vascular Insufficiency Is Not Associated with HLA DRB1*1501 Status in Multiple Sclerosis Patients. <i>PLoS ONE</i> , 2011, 6, e16802.	1.1	14
52	A randomized, blinded, parallel-group, pilot trial of mycophenolate mofetil (CellCept) compared with interferon beta-1a (Avonex) in patients with relapsing-remitting multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2010, 3, 15-28.	1.5	29